Table 1.

General and intraoperative data for the two groups of patients receiving balanced anaesthesia or total intravenous anaesthesia

	Balanced anaesthesia	TIVA	p
Age (years)	75 ± 7	74 ± 6	0.464
Gender (nr, % of males)	16, 80%	18, 90%	0.376
ASA score (nr, %)			0.127
2	13, 65%	18, 90%
3	7, 35%	2, 10%
Comorbidities (nr, %)
Arterial hypertension	20, 100%	18, 90%	0.149
Cardiopathy	6, 30%	10, 50%	0.197
Renal Failure	3, 15%	5, 25%	0.429
COPD	12, 60%	8, 40%	0.206
Dyslipidaemia	10, 50%	10, 50%	0.999
Vasculopathy (lower limbs or carotid)	10, 50%	8, 40%	0.525
Clamping time (min)	65 ± 29	69 ± 31	0.691
Fluid balance (ml)	−200 [− 1100 − + 150]	− 195 [−670 − + 300]	0.657
Norepinephrine
number, %	20, 100%	20, 100%	0.999
mean dosage (mcg/kg/min)	0.15 [0.08–0.20]	0.12 [0.09–0.15]	0.466
Dobutamine
number, %	13, 65%	16, 80%	0.288
mean dosage (mcg/kg/min)	2.00 [1.23–3.00]	2.39 [1.67–3.92]	0.416
Esmolol (nr, %)	14, 70%	10, 50%	0.197
Levosimendan (nr, %)	3, 15%	5, 25%	0.429
Blood transfusions
number, %	10, 50%	10, 50%	0.999
average amount (ml)	540 [450–1060]	580 [450–780]	0.837

Data are expressed as mean ± standard deviation or median [1st-3rd quartile], as appropriate

Cardiopathy was defined by the presence of echocardiographic alterations including left ventricular hypertrophy and valvulopathy, or a history of coronary artery disease and/or heart failure and reduced left ventricular ejection fraction. Renal failure was defined by the presence of an estimated glomerular filtration rate lower than 60 ml/min/1.73mq

TIVA total intravenous anaesthesia, ASA American Society of Anesthesiology, COPD chronic obstructive pulmonary disease